Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
citalopram + pindolol
- Development stage
- Phase 4
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and pindolol, a nonselective beta blocker. This combination has been studied for enhanced antidepressant effects, as pindolol may potentiate the action of citalopram by increasing serotonin synthesis in the brain.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)ADRB1 (β1)ADRB2 (β2)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on citalopram + pindolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on citalopram + pindolol.